secwatch.observer — SEC 8-K summary
======================================

Issuer:     MAXCYTE, INC. (MXCT)
CIK:        0001287098
Form:       8-K
Filed at:   2025-11-05T23:59:59+00:00
Accession:  0001104659-25-107118
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MaxCyte reports preliminary Q3 2025 revenue of $6.8M, down 16% YoY; reiterates FY2025 guidance
--------------------------------------------------------------------------------

- Total revenue $6.8M, core revenue $6.4M (-21% YoY); adds three new SPL clients including Moonlight Bio.
- Gross margin 77%; non-GAAP adjusted gross margin 81% (excl. SPL program revenue and inventory reserves).
- Rescheduled Q3 earnings call to Nov 12, 2025 due to impairment testing of goodwill and long-lived assets; no prior quarter impact.
- Cash and investments $158.0M at Sept 30, 2025; expects year-end cash $152-155M reflecting restructuring costs.
- Reiterates FY2025 core revenue guidance: flat to -10% vs 2024; SPL program-related revenue ~$5M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1287098/000110465925107118/0001104659-25-107118-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1287098/000110465925107118/mxct-20251105x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-107118

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer